Sort
82,697 grants matching “vaccine development”
IMPAACT, RANDOMIZED TRIAL TO EVALUATE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT REGIMENTS IN HIV INFECTED WOMEN
$892,210Driver Barbara · Westat, Inc. · N01 · FY2018 · HD
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease
$892,209Gary Fanger · Rise Therapeutics, Llc · R44 · FY2020 · DK
Childhood Leukemia and Environmental Exposures
$892,145Patricia A Buffler · University Of California Berkeley · R01 · FY2008 · ES
Role of Regulatory T Cells in Parasitic Infections
$892,072Yasmine Belkaid · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates
$892,055Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2020 · AI
A Mucosal Vaccine for HSV-2
$891,829Kejian Yang · Biomedical Research Models, Inc. · R44 · FY2009 · AI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein
$891,695Kevin Trabbic · Bluewillow Biologics, Inc. · R44 · FY2024 · AI
An Env apex-focused HIV-1 vaccine strategy
$891,681Michael R. Farzan · Boston Children'S Hospital · R01 · FY2024 · AI
Development of RespiraClear for targeted mucosal treatment of RSV infections
$891,585Richard A Cone · Mucommune, Llc · R44 · FY2022 · AI
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
$891,540Sung Hwan Cho · Nanocellect Biomedical, Inc. · R44 · FY2022 · GM
Identification of the Initial Targets of Transmission
$891,413Thomas Hope · Northwestern University At Chicago · R37 · FY2025 · AI
Therapeutic vaccination to boost autologous neutralizing antibodies for ART free HIV Control
$891,410Katharine June Bar · University Of Pennsylvania · R37 · FY2025 · AI
Identification of the Initial Targets of Transmission
$891,371Thomas Hope · Northwestern University At Chicago · R37 · FY2024 · AI
Units for HIV/AIDS Clinical Trials Networks
$891,320Ram Yogev · Lurie Children'S Hospital Of Chicago · U01 · FY2010 · AI
Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials
$891,242Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Development of PSMA -based recombinant protein vaccines
$891,229Gerald P Donovan · Progenics Pharmaceuticals, Inc. · R44 · FY2006 · CA
Expediting elicitation of HIV-1 bnAbs with membrane Env vaccines
$891,174Michael B Zwick · Scripps Research Institute, The · R01 · FY2023 · AI
Inhibitors of Anthrax Lethal Factor Metalloproteinase
$891,165Alan Thomas Johnson · Panthera Biopharma, Llc · R44 · FY2009 · AI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS
$891,161Shiu-Lok Hu · University Of Washington · R01 · FY2019 · AI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS
$891,161Shiu-Lok Hu · University Of Washington · R01 · FY2021 · AI
Approaches to Improve the Efficacy of Prime-boost Immunization against HIV/AIDS
$891,161Shiu-Lok Hu · University Of Washington · R01 · FY2020 · AI
NIAID DAIDS Global Enterprise on HIV Vaccine
$891,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2015 · AI
NIAID DAIDS Global Enterprise on HIV Vaccine
$891,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2014 · AI
Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunity
$890,998Norberto Gonzalez-Juarbe · Univ Of Maryland, College Park · R01 · FY2024 · AI
Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles
$890,878David B. Weiner · Wistar Institute · P01 · FY2025 · AI